| Scientific Name |
Ciltacabtagene Autoleucel
|
|---|---|
| Brand Name |
CARVYKTI
|
| Risk |
Potential risk of T-cell malignancy associated with the use of chimeric antigen receptor (CAR) T cell Immunotherapies
|
| Educational Materials for Healthcare Professionals |
|
| Safety Communication for Healthcare Professionals |
|
| Educational Materials for Patients |
|